Live Breaking News & Updates on Christiem Ballantyne

Stay updated with breaking news from Christiem ballantyne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New Guidance in Lowering LDL-C

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk. ....

Bogalusa , Louisiana , United-states , Payal-kohli , Christiem-ballantyne , Keithc-ferdinand , Erind-michos , Cardiology-expert-consensus-decision-pathway , Bogalusa-heart-study , Consensus-decision-pathway , South-asian

LDL-C and Cardiovascular Disease Risk

Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis. ....

Colorado , United-states , Texas , New-orleans , Louisiana , Houston , Keithc-ferdinand , Erin-michos , Mary-mcgowan , Christie-ballantyne , Christiem-ballantyne , Geralds-berenson

Healio partners with CMHC for annual congress

Healio partners with CMHC for annual congress
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Georgel-bakris , Scott-buzby , Annel-peters , Christiem-ballantyne , Roberth-eckel , Cardiometabolic-health-congress , Digital-advances-in-cardiorenal-metabolic-health , Annual-cardiometabolic-health-congress , Social-determinants , Digital-advances , Cardiorenal-metabolic

The Evolving Narrative of HDL-C: Contemporary Insights on Quality vs. Quantity for Targeting Cardio Protection

The Evolving Narrative of HDL-C: Contemporary Insights on Quality vs. Quantity for Targeting Cardio Protection
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Baylor-college-of-medicine , Texas , United-states , Houston , New-york , American , Veraa-bittner , Roberts-rosenson , Christiem-ballantyne , Astra-zeneca , Eli-lilly , Kathleenh-byrne

Combination Obicetrapib plus Ezetimibe Shows Promise for Dyslipidemia in Phase 2 Trial

New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe. ....

John-kastelein , Christiem-ballantyne , York-heart-association-functional-classification-class , National-lipid-association , Newamsterdam-pharma-company , Baylor-college-of-medicine , Cardiovascular-research , Baylor-college-of-medicine-christie-ballantyne , Baylor-college , Christie-ballantyne , Scientific-sessions , Consensus-decision-pathway